The Everything Pill
Summary
Host Jack Howe and Morgan Stanley’s Terrence Flint discuss GLP-1 drugs as a major profit driver, rivaling AI. They analyze Eli Lilly’s market lead over Novo Nordisk, the rise of oral pills, and expanding indications beyond weight loss. The episode also covers Medicare coverage changes, patent cliffs, and how improved metabolic health could significantly boost global GDP.
Topics discussed
Introduction and sponsor message from Baird
Host intro: The 'everything drug' and personal weight loss journey
GLP-1 market growth, AI comparison, and new indications
Medicare coverage changes and insurance cost reductions
Novo Nordisk vs. Eli Lilly: Injectables vs. Pills
Next-gen drugs: Retatrutide and Alluralintide
Interview with Terrence Flynn on market uptake and competitors
Commercial break and sponsor messages
Stock performance, patent cliffs, and manufacturing challenges
Continued interview: Patent strategy and future market size
Societal impact: Obesity rates, GDP, and healthy longevity
Conclusion and final sponsor message from Charles Schwab
Listen ad-free on Castria